Yuqori xavfli terapiyaga individual yondashuv: gipertenziya va giperlipidemiyaga qarshi dorilarning majmuaviy va alohida kombinatsiyalarini solishtirma baholash.
Annotatsiya
Maqsad. Boshqarilmaydigan arteriyal gipertenziya yuqori va juda yuqori yurak-qon tomir xavfi bo‘lgan bemorlarda zamonaviy tibbiyotning muhim muammosi bo‘lib qolmoqda. Arterial bosimni boshqarish va yurak-qon tomir nojo‘ya ta'sirlarini kamaytirish uchun doimiy yoki alohida preparatlar kombinatsiyasidan foydalanish, anti-gipertenziya terapiyasini optimallashtirish uchun istiqbolli yondashuvdir.
Materiallar va metodlar. Tadqiqotga 40 nafar bemor (erkaklar va ayollar) kiritildi, ular ESC/ESH (2018) tasnifi bo‘yicha I-III darajadagi arteriyal gipertenziya bilan kasallangan. O‘rtacha yosh 51,52 ± 9,43 yilni, kasallik davomiyligi esa 8,52 ± 6,64 yilni tashkil etdi. Bemorlar ikki guruhga bo‘lingan: biri doimiy kombinatsiyani (lizinopril/amlodipin/rozuvastatin), ikkinchisi esa alohida kombinatsiyani (perindopril/amlodipin va rozuvastatin) qabul qilgan. Davolash 3 oy davomida o‘tkazildi. Samara, kunlik arterial bosim monitoringi, applanatsion tonometriya, ehokardiografiya, braxiotsefalik arteriyalarni ultratovush tekshiruvi va laborator tahlillar (lipid profili, glyukoza darajasi, siydik kislota va kreatinin) orqali baholandi.
Natijalar. Har ikkala davolash rejimi yuqori anti-gipertenziya, organ-protektiv va gipolipidemik samaradorlikni ko‘rsatdi. Ammo doimiy kombinatsiyani qabul qilgan bemorlarda sistolik va diastolik arterial bosimning sezilarli darajada kamayishi, lipid profilining yaxshilanishi va tungi arterial bosimning o‘zgaruvchanligining kamayishi kuzatildi. Metabolik profilga salbiy ta'sir ko‘rsatilgani aniqlanmadi.
Xulosa. Doimiy preparatlar kombinatsiyasi alohida sxemaga nisbatan ustunlikni ko‘rsatdi, arterial bosimni yaxshiroq nazorat qilish va lipid profilini yaxshilashni ta'minladi. Ushbu natijalar yuqori yurak-qon tomir xavfi bo‘lgan bemorlar uchun optimal terapiya rejalarini tanlash zarurligini ta'kidlaydi va ushbu bemorlar guruhida doimiy kombinatsiyalar samaradorligini tasdiqlaydi.
Mualliflar haqida
Adabiyotlar ro'yxati
Acelajado M.C., Hughes Z.H., Oparil S., Calhoun D.A., Treatment of resistant and refractory hypertension, Circulation Research, 2019, 124, 07, 1061–1070, 10.1161/CIRCRESAHA.118.312156.
Cicero A.F.G., ALGhasab N.S., Tocci G., Desideri, G., Fiorini G., Fogacci F., Efficacy and safety of low-dose bisoprolol/hydrochlorothiazide combination for the treatment of hypertension: A systematic review and meta-analysis, Journal of Clinical Medicine, 2024, 13, 015, 4572, 10.3390/jcm13154572.
Dola´n E., Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients – an Anglo-Scandinavian cardiac outcomes trial substudy, Journal of Hypertension, 2009, 27, 04, 876–885, 10.1097/HJH.0b013e328322cd62.
Jamerson K., Shi V., Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients, New England Journal of Medicine, 2008.
Roth G.A., Global burden of cardiovascular diseases and risk factors, 1990–2019, Journal of the American College of Cardiology, 2020, 76, 025, 2982–3021, 10.1016/j.jacc.2020.11.010.
Sarzan´ı R., Laureti G., Gezzi A., Spannella F., Giulietti F., Single-pill fixed-dose drug combinations to reduce blood pressure: The right pill for the right patient, Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211027, 10.1177/20406223221102754.
Schutte A.E., Srinivasapura N.Venkateshmurthy, Mohan S., Prabhakaran D., Hypertension in low- and middle-income countries, Circulation Research, 2021, 128, 07, 808–826, 10.1161/CIRCRESAHA.120.318729.
Sever P.S., The Anglo-Scandinavian Cardiac Outcomes Trial: Implications and further outcomes, Hypertension, 2012, 60, 02, 248–259, 10.1161/HYPERTENSIONAHA.111.187070.
Unge´r T., 2020 International Society of Hypertension global hypertension practice guidelines, Journal of Hypertension, 2020, 38, 06, 982–1004, 10.1097/HJH.0000000000002453.
Virani S.S., Heart disease and stroke statistics—2020 update: A report from the American Heart Association, Circulation, 2020, 141, 09, e139–e596, 10.1161/CIR.0000000000000757.
Wald N.J., Law M., Blood pressure meta-analysis highlights an implementation gap, The Lancet, 2022, 399, 010333, 1379–1380, 10.1016/S0140-6736(22)00192-1.
Sever P.S., Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations. Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm, Lancet, 2003, 361, 09364, 1149–1158, 10.1016/S0140-6736(03)12948-0.
Cequier A´ ., Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy
elevado, REC CardioClinics, 2021, 56, 01, 39–48, 10.1016/j.rccl.2020.10.017.
Schutte A., Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high- and very high-risk patients, Circulation Clinical Trials, 2023.
Jamerson K., Shi V., Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients, New England Journal of Medicine, 2008.
European Society of Cardiology, Polypill strategy reduces cardiovascular events in heart attack patients, ESC Press Releases, Retrieved from https://www.escardio.org, 2023.
Poulter N.R., Role of blood pressure and other variables in the differential cardiovascular event rates noted in the ASCOT-BPLA, Lancet, 2009, 373, 09656, 1177–1183, 10.1016/S0140-6736(09)60316-8.
Unger T., Single-pill fixed-dose drug combinations for blood pressure and lipid lowering: Practice guidelines, Journal of Hypertension, 2020, 38, 06, 1046–1060, 10.1097/HJH.0000000000002390.
Sever P.S., Prevention of coronary heart disease and stroke in hypertensive patients with lipid abnormalities, Hypertension Journal, 2015.
Dolan E., Benefits of intensive antihypertensive therapy in preventing cardiovascular disease in high-risk patients, Hypertension, 2010.
Ushbu asar saytida mavjud litsenziyalar Creative Commons «Attribution-NonCommercial-ShareAlike» («Atribut - notijorat maqsadlarda foydalanish - bir xil shartlar») 4.0 Всемирная.